Latest News - Thermo Fisher Scientific
Top Corporates Hub
Thermo Fisher Scientific
On the Eve of BIO 2026, Chinese Innovative Assets Trigger a New Wave of Global Collaborations
08.07.2026 16:00
On the eve of the highly anticipated BIO International Convention 2026, the BIOSeedin Summer Innovation Partnering Summit successfully took place in San Diego. Hosted by bioSeedin and proudly supported by strategic partners Thermo Fisher Scientific and ACROBiosystems, the summit was uniquely designed as an international roadshow and licensing matchmaking platform dedicated to showcasing China's differentiated innovative assets.
Cell Culture Media Market worth $12.9 billion by 2033: Biologics Manufacturing and Cell Therapy Expansion Accelerate Growth for Avantor, Thermo Fisher Scientific, and Lonza Group AG
08.07.2026 15:54
Persistence Market Research, a leading management consulting firm, has released this update on the cell culture media market. These specialized nutrient formulations provide the essential environment for growing and maintaining cells used in biopharmaceutical manufacturing, vaccine production, regenerative medicine, and advanced biomedical research.
9 Health Care Stocks Whale Activity In Today’s Session
08.07.2026 13:35
This whale alert can help traders discover the next big trading opportunities. Whales are entities with large sums of money and we track their transactions here at Benzinga on our options activity scanner. Traders will
Thermo Fisher Scientific Receives First FBI Approval for Rapid DNA Crime Scene Profiles Eligible for National CODIS Searches
07.07.2026 12:30
SAN FRANCISCO, July 07, 2026--Thermo Fisher Scientific, the world leader in serving science, today announced that the Applied Biosystems™ RapidINTEL™ Plus Cartridge has received approval from the Federal Bureau of Investigation (FBI) National DNA Index System (NDIS) for use with qualifying forensic crime scene samples. The law enforcement milestone makes Thermo Fisher's Rapid DNA workflow on the RapidHIT ID™ System the first eligible to generate DNA profiles that can be searched against the nati
Surplus Solutions, an NMS Capital Portfolio Company, Accelerates Technical Service Capabilities; Announces Partnership with DCM BioServices
06.07.2026 17:14
Surplus Solutions LLC ("Surplus Solutions"), a portfolio company of NMS Capital ("NMS"), announced today the acquisition of DCM BioServices ("DCM Bio" or the "Company"), a Frederick, Maryland-based provider of laboratory automation maintenance, repair, technical support, and integration solutions. The acquisition expands Surplus Solutions' technical service capabilities and supports the Company's continued growth in the biotechnology, pharmaceutical, and life sciences sectors. Terms of the trans
Medpace: The Recovery Narrative Looks Premature
06.07.2026 14:28
Medpace's outlook turns cautious as bookings, backlog, and cancellations worsen vs. CRO peers. Click for more on MEDP stock.
Top 10 medtech deals in the first half of 2026
06.07.2026 10:00
Boston Scientific, Medtronic and Stryker were among the companies to ink deals to move into markets that are expanding quickly.
Arcturus Therapeutics (ARCT) Stock Jumps 5.7%: Will It Continue to Soar?
03.07.2026 11:06
Arcturus Therapeutics (ARCT) saw its shares surge in the last session with trading volume being higher than average. The latest trend in earnings estimate revisions may not translate into further price increase in the near term.
Thermo Fisher, Arcturus partner on Phase III ARCT-032 cystic fibrosis trial
03.07.2026 08:31
Thermo Fisher will provide integrated manufacturing, clinical research and commercial readiness services.
Arcturus Picks Thermo Fisher To Support Cystic Fibrosis Therapy
02.07.2026 11:32
Arcturus partners with Thermo Fisher to support Phase 3 development and potential commercialization of ARCT-032 for cystic fibrosis.
Arcturus Therapeutics Announces Strategic Collaboration with Thermo Fisher Scientific to Advance ARCT-032 for Cystic Fibrosis
02.07.2026 11:00
SAN DIEGO, July 02, 2026--Arcturus Therapeutics Holdings Inc. ("Arcturus", Nasdaq: ARCT), a messenger RNA medicines company focused on the development of liver and respiratory rare disease therapeutics, today announced a strategic collaboration with Thermo Fisher Scientific, the world leader in serving science, to help support the Phase 3 development and potential commercialization of ARCT-032, Arcturus’ investigational mRNA therapy for Cystic Fibrosis.
Arcturus Therapeutics Collaborates With Thermo Fisher Scientific To Help Support Phase 3 Development And Potential Commercialization Of ARCT-032, Investigational mRNA Therapy For Cystic Fibrosis
02.07.2026 07:02
Strategic manufacturing agreement includes Phase 3 clinical supply and commercial manufacturing rightsArcturus Therapeutics Holdings Inc. (("Arcturus", NASDAQ:ARCT), a messenger RNA medicines company focused on
AustinPx Expands KinetiSol™ Technology Commercial Access through Thermo Fisher Scientific Collaboration
30.06.2026 13:00
GEORGETOWN, Texas, June 30, 2026--AustinPx, a contract development and manufacturing organization (CDMO) specializing in bioavailability enhancement for orally delivered small molecule drugs, today announced its agreement with Thermo Fisher Scientific’s Patheon pharma services for the installation of AustinPx’s KinetiSol™ Technology equipment.
Thermo Fisher Scientific: Gradually Getting Cheaper
29.06.2026 01:57
Thermo Fisher's recent $1.075B microbiology business sale was at a low 1.7x sales multiple and is dilutive to EPS. Read why TMO stock is a Hold.
Is Danaher (DHR) One of the Best Non-Tech Stocks to Buy According to Analysts?
28.06.2026 16:45
Danaher Corporation (NYSE:DHR) is one of the best non-tech stocks to buy according to analysts. Masimo, Danaher Corporation’s (NYSE:DHR) specialty diagnostics solutions innovator of pulse oximetry and other patient monitoring solutions, announced on June 22, FDA 510(k) clearance for an opioid-induced respiratory depression detection capability integrated into the Radius VSM® wearable continuous patient monitor. Supported […]
Bernstein Says Life Science Sector is Improving, Resumes Thermo Fisher Scientific (TMO) Coverage
28.06.2026 03:54
Thermo Fisher Scientific Inc. (NYSE:TMO) is included among Billionaire Steven Cohen’s Top 11 Dividend Stock Picks. On June 26, Bernstein resumed coverage of Thermo Fisher Scientific Inc. (NYSE:TMO) with a Market Perform rating. It also set a $520 price target after the analyst returned from maternity leave. In a research note, the firm said “Many […]
Global Cell Therapy Human Raw Materials Market Size/Share Worth USD 18.94 Billion by 2035 at a 16.3% CAGR: Healthcare Foresights (Analysis, Outlook, Leaders, Report, Trends, Forecast, Segmentation, Growth Rate, SWOT Analysis)
25.06.2026 08:30
[220+ Pages Latest Report] According to a market research study published by Healthcare Foresights, the demand analysis of Global Cell Therapy Human Raw Materials Market size & share revenue was valued at approximately USD 3.62 Billion in 2025 and is expected to reach USD 4.21 Billion in 2026 and is expected to reach around USD 18.94 Billion by 2035, at a CAGR of 16.3% between 2026 and 2035. The key market players listed in the report with their sales, revenues and strategies are Thermo Fisher S
Thermo Fisher Scientific Showcases New Capabilities Across Manufacturing, Clinical Development and AI-Enabled Research at BIO International 2026
22.06.2026 12:30
WALTHAM, Mass., June 22, 2026--Thermo Fisher Scientific, the world leader in serving science, will showcase new capabilities, strategic investments and initiatives at BIO International 2026 that are helping pharma and biotech customers advance innovation, simplify complex workflows and bring therapies to patients faster.
3 Reasons TMO is Risky and 1 Stock to Buy Instead
18.06.2026 10:53
Over the last six months, Thermo Fisher’s shares have sunk to $464.50, producing a disappointing 17.4% loss - a stark contrast to the S&P 500’s 10.9% gain. This might have investors contemplating their next move.
Avantor (AVTR) Gets Underperform Rating From Wolfe Research
17.06.2026 09:59
Avantor, Inc. (NYSE:AVTR) is one of the 10 Best Stocks to Buy Under $10. On June 1, Wolfe Research initiated coverage on Avantor, Inc. (NYSE:AVTR), giving the stock an Underperform rating and setting the price target at $7. The research firm noted that the company has seen multiple years of growth and margin challenges. Revenue […]